Ben-Gurion University of the Negev

Medigus Announces Record 2022 First Half Financial Results

Retrieved on: 
Friday, September 23, 2022
MOU, Nasdaq, Safety, TEL, TASE, Severe acute respiratory syndrome coronavirus 2, OTCQB, Company, Private Securities Litigation Reform Act, Israel Gymnastics Federation, Aviation, Jersey Table Tennis Association, Investment, Digital, Ownership, Tennis, CEO, Solution, MDGS, GLOBE, Ben-Gurion University of the Negev, SEC, Israeli Basketball Premier League, Robotics, Online gambling, Video game, Cryptocurrency, Satellite navigation device

TEL AVIV, Israel, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Medigus Ltd. (Nasdaq: MDGS) (Medigus), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle and charging solutions, today reported financial results for the six months ended June 30, 2022.

Key Points: 
  • TEL AVIV, Israel, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Medigus Ltd. (Nasdaq: MDGS) (Medigus), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle and charging solutions, today reported financial results for the six months ended June 30, 2022.
  • Generated record revenues of $34.95 million in the first half of 2022, compared to $2.39 million revenues in the first half of 2021
    Gross profit reached a record $6.19 million in the first half of 2022, up from a gross profit of $0.6 million in the first half of 2021
    Cash and cash equivalents as of June 30, 2022 were $22.1 million
    Shareholders equity improved to $53.19 million as of June 30, 2022, up from $51.43 million at December 31, 2021
    Our record first half of 2022 financial results are a direct result of our work over the past two years and clearly demonstrate the value in our approach to engage in innovative technology companies with high upside potential, said Liron Carmel, CEO of Medigus.
  • Eventer, in which Medigus has a 46.21% ownership stake, achieved record revenues, which increased by 221% year-over-year to approximately $1.4 million in the first half of 2022.
  • ScoutCam, in which Medigus has a 27.02% ownership stake, completed verification & validation for miniature camera solution with a Fortune 500 customer.

Maris-Tech and Ben Gurion University Received a Joint Grant for the Development of Advanced System for Drones Fault Prediction

Retrieved on: 
Wednesday, August 24, 2022
Machine learning, Technology, CEO, Securities Exchange Act of 1934, Program, Securities Act of 1933, Artificial intelligence, RF, Veteran, SEC, ML, Organization, HLS, GLOBE, Intention, Company, Ben-Gurion University of the Negev, Annual report, Forward-looking statement, Risk management

REHOVOT, Israel, Aug. 24, 2022 (GLOBE NEWSWIRE) --  Maris-Tech Ltd. (Nasdaq: MTEK) (“Maris-Tech” or the “Company”), a B2B provider of intelligent video transmission technology, today announced it has received a joint grant with Ben Gurion University, Be'er Sheva, Israel, from the Israeli Innovation Authority.

Key Points: 
  • "We are honored to receive this grant with a leading university like Ben Gurion and consider this grant as a vote of confidence in our technology.
  • After assessing the project, the combination of both technologies, and our ability to deliver advance products, the Company was awarded the grant.
  • It is our intention to continue partnering with leading organizations and harness our products' advantages to additional sectors and systems.
  • This program is another layer in the Companys intention to provide edge computing solutions on drones".

Translational Research Describes an Epigenetic Approach for Regulating Fear-Memory

Retrieved on: 
Monday, August 22, 2022
Memorial Day, Nature, University, Icahn School of Medicine at Mount Sinai, Ben-Gurion University of the Negev, CEO, Perelman School of Medicine at the University of Pennsylvania, UC, Wood, Research, Neuron, Gene, Time, Doctor of Philosophy, Penn, Psychiatry, Memory, Acetyl-CoA, Mouse, Anxiety, Acetyl group, ACSS2, Mount Sinai, National, RATS, Addiction, Alzheimer's disease, Animal, University of Pennsylvania, Post-traumatic stress disorder, National academy, Fear, Lists of diseases, Yale University, Therapy, Adult, Trauma, Mews, University of California, Irvine, Intellectual property, Urine, Memory consolidation, Pharmaceutical industry, Vaccine, Meat, PTSD, PNAS

PHILADELPHIA, Aug. 22, 2022 /PRNewswire/ -- EpiVario, Inc., an emerging biotech company developing novel therapeutics for memory-related psychiatric disorders, today highlighted preclinical research findings that could lead to a treatment approach for PTSD. Published in Proceedings of the National Academy of Sciences (PNAS), and co-authored by the academic co-founders of EpiVario, the study demonstrates that fear memories can be controlled through the enzyme acetyl-CoA synthetase 2 (ACSS2). The team also confirmed that a small molecule inhibitor against ACSS2 can block the epigenetic process required for the consolidation of stress and fear memories. 

Key Points: 
  • The team also confirmed that a small molecule inhibitor against ACSS2 can block the epigenetic process required for the consolidation of stress and fear memories.
  • Investigational small molecule compounds were provided by EpiVario, which is developing ACSS2 inhibitors as a therapeutic for memory related neuropsychiatric disorders.
  • "These new results are exciting, as they validate our earlier discovery that ACSS2 is critical for activating genes during the creation of fear memories.
  • These memories are attenuated via epigenetic regulation through the target enzyme acetyl-coA synthetase 2 (ACSS2), which regulates consolidation of fear and drug-craving memories.

Fairtility Launches AI Academy to Demystify Use of Artificial Intelligence in Fertility Care

Retrieved on: 
Tuesday, July 26, 2022
Gynaecology, Knowledge, Education, Clinical research, Ben-Gurion University of the Negev, Industry, Obstetrics, Twitter, Ethics, CEO, Annual general meeting, Infertility, Human Reproduction (journal), University Medical Center Schleswig Holstein, Associate, ESHRE, Engineering, Weill Cornell Medical College in Qatar, Adoption, European Society for Primary Immunodeficiencies, Bachelor of Engineering, Technology, Information system, LinkedIn, Patient, Reproductive medicine, Digital health, Department, IVF, Entrepreneurship, Health care, TEL, Medical device, Fertility, Software, AI, Embryology

TEL AVIV, Israel, July 26, 2022 /PRNewswire/ -- Fairtility, the transparent AI innovator powering in vitro fertilization (IVF) for improved outcomes, announced the launch of the AI Academy, a new educational platform that will host healthcare and technology experts to engage the IVF community in the conversation around the responsible adoption of AI innovation in IVF care. 

Key Points: 
  • Fairtility launched the AI Academy at the European Society of Human Reproduction and Embryology (ESHRE) 38th Annual Meeting, which took place in Milan, Italy, July 3-6.
  • Dr. Gerard Letterie, a leader in reproductive endocrinology and infertility specialist at Seattle Fertility, serves as the Academic Head of the AI Academy.
  • "Our goal with the AI Academy is to provide the needed education, bringing IVF professionals into the conversation on AI transformation for fertility care.
  • For further information or to register for AI Academy, visit: www.fairtility.com/AIAcademy
    Fairtility is powering in vitro fertilization (IVF) through transparent AI to improve outcomes.

BUFFERZONE Appoints Ran Dubin as CTO to Boost Zero Trust Solutions Development

Retrieved on: 
Monday, July 18, 2022
Zero, APTS, CEO, Super Mario, Doctor of Philosophy, Artificial intelligence, Engineering, Deep learning, Technology, TEL, CTO, Female gendering of AI technologies, Ben-Gurion University of the Negev, Organization, Industry, Internet, Medical imaging, Online shopping, Medical device, RadCom

TEL AVIV, Israel, July 18, 2022 /PRNewswire/ -- BUFFERZONE, a provider of next-generation endpoint security solutions which protect organizations from advanced threats such as ransomware, zero-days and phishing scams, has appointed Dr. Ran Dubin as the company's CTO as part of the company's efforts to add another layer to its Safe Workspace solution by combining phishing and fraud protection with endpoint containment and isolation.

Key Points: 
  • Prior to joining BUFFERZONE, Dr. Dubin was the cofounder and CEO of SNDBOX, which was acquired by OPSWAT.
  • "By adding AI capabilities to BUFFERZONE's existing Safe Workspace solutions, the company will be able to offer protection at an affordable cost," said Dr. Dubin.
  • BUFFERZONE Safe Bridge enables downloads, attachments and files from removable devices to be disarmed for secure extraction from the container.
  • BUFFERZONE is a registered trademark of BUFFERZONE Security Ltd. All other trademarks are the property of their respective owners.

Former Lucid Diagnostics Chief Medical Officer, David Wurtman, Joins NDA Partners as Expert Consultant

Retrieved on: 
Thursday, June 23, 2022
Ben-Gurion University of the Negev, Internal medicine, Family office, Department, FDA, NDA, IPO, MBA, MIT Sloan School of Management, Private equity, Partner, Harvard Medical School, John Gibbs (US government official), Government, CEO, USP, Mount Auburn, Business, Pharmacokinetics, Venture capital, Biotechnology, PDL BioPharma, Genzyme, Federal government of the United States, Public, MD, Program, CMO, Harvard University, Hospital, Weizmann Institute of Science, Toxicology, CMC, ICU, 25, Management, Medical device

WASHINGTON, June 23, 2022 /PRNewswire-PRWeb/ -- NDA Partners General Manager, Eric Fish, announced today that David Wurtman, MD, MBA, an experienced business executive and product development expert, has joined the company as an Expert Consultant. Dr. Wurtman joined the firm to support companies with corporate strategy, fundraising, mergers & acquisitions, business development & licensing, product development, market research, product positioning, and, clinical-regulatory strategy and development. He has particular expertise in assisting emerging and start-up product and platform companies.

Key Points: 
  • NDA Partners General Manager, Eric Fish, announced today that David Wurtman, MD, MBA, an experienced business executive and product development expert, has joined the company as an Expert Consultant.
  • Dr. Wurtman formerly served as Chief Executive Officer of Lyric Pharmaceuticals, an ICU therapeutic development company, and Chief Medical Officer of Lucid Diagnostics.
  • WASHINGTON, June 23, 2022 /PRNewswire-PRWeb/ -- NDA Partners General Manager, Eric Fish, announced today that David Wurtman, MD, MBA , an experienced business executive and product development expert, has joined the company as an Expert Consultant.
  • Dr. David Wurtman earned his medical degree from Harvard Medical School and MBA from MIT Sloan School of Management.

Neuromagen Pharma Announces the Appointment of Professor Gal Ifergane, Head of the Neurology Department at Soroka Medical Center, to its Scientific Advisory Board

Retrieved on: 
Thursday, June 23, 2022
Fertility, Education, COVID-19, Stroke, Degenerative disease, CEO, Coronavirus Scientific Advisory Board (Turkey), Soroka Medical Center, Research, Cellular senescence, PTSD, Neurodegeneration, Alzheimer's disease, Ben-Gurion University of the Negev, Patient, Headache, ALS, Medical Center, TERT, Pharmaceutical industry

BE'ER SHEVA, Israel, June 23, 2022  /PRNewswire/ -- Neuromagen Pharma Ltd., a company developing a new class of drugs for the treatment of degenerative and senescence-associated diseases, announced today the establishment of a Scientific Advisory Board and the appointment of Prof. Gal Ifergane, Head of the Neurology Department at Soroka Medical Center as its first member.

Key Points: 
  • Gil Ben-Menachem, Neuromagen's CEO said: "Prof. Ifergane brings to Neuromagen extensive expertise within the neurology field.
  • "I am delighted to join Neuromagen's Scientific Advisory Board," stated Professor Ifergane.
  • Prof. Gal Ifergane completed his education and training in Ben Gurion University and Soroka Medical Center in Be'er Sheva, Israel.
  • Since 2012 he has been serving as the Head of Soroka's Medical Center Neurology department.

Bragg Gaming Names Yaniv Sherman Chief Executive Officer

Retrieved on: 
Monday, June 13, 2022
Online Retail, Entertainment, Consumer Electronics, Retail, Technology, General Entertainment, Electronic Games, Leadership, Head, Company, Marketing, Sports Illustrated, PAM, MBA, RGS, Delaware Lottery, LSE, Software, Senior, Intelligence, Growth, Ben-Gurion University of the Negev, Technology, Trade, BRAG, Acquisition, TSX, NASDAQ, Wild Streak, Industry, Board, Caesars Entertainment, ORYX, IGaming Business, Intention, Sport, 888 Holdings, B2B, Online gambling, Video game

Bragg Gaming Group ( NASDAQ: BRAG , TSX: BRAG ) (Bragg or the Company), a global iGaming technology and content provider, announced today that it will appoint Yaniv Sherman as the Companys new Chief Executive Officer, effective July 1, 2022.

Key Points: 
  • Bragg Gaming Group ( NASDAQ: BRAG , TSX: BRAG ) (Bragg or the Company), a global iGaming technology and content provider, announced today that it will appoint Yaniv Sherman as the Companys new Chief Executive Officer, effective July 1, 2022.
  • Mr. Sherman brings to Bragg more than 20 years of experience in leading global teams across the gaming, software and online gaming sectors, including, most recently, 15 years as a senior executive at 888 Holdings plc (LSE: 888).
  • Mr. Sherman joins Bragg Gaming Group from 888 Holdings plc, where he served as Senior Vice President and Head of U.S. from 2018 to 2021.
  • Commenting on Mr. Shermans appointment, Braggs Chairman of the Board, Paul Godfrey, said, Were delighted to welcome Yaniv Sherman to Bragg Gaming Group as our new Chief Executive Officer.

Citrine Global Corp. (OTCQB: CTGL) Announces Prof. Itamar Grotto, a World-Renowned Expert in Public Health, Joining the Company’s Israeli Subsidiary Board of Directors, and Appointed as President of Green Vision Center Israel

Retrieved on: 
Tuesday, May 31, 2022
CEO, Research and development, Company, Private Securities Litigation Reform Act, Public health, Research, World, Nasdaq, Board of directors, Public sector, World Health Organization, Federal Executive Boards, Government, Ben-Gurion University of the Negev, Quality of life, Associate, 10 Essential Public Health Services, Ministry, Technology, Board, Communication, Cyprus University of Technology, Former, Greens Siding railway station, National health insurance, SEC, Development, OTCQB, Laboratory, Negev, Risk, Annual report, GLOBE, Management, Fine chemical, Security (finance), Health

Tel Aviv, May 31, 2022 (GLOBE NEWSWIRE) -- Citrine Global Corp. (OTCQB: CTGL) is pleased to announce Prof. Itamar Grotto joining the Board of Directors of the Companys Israeli subsidiary, Cannovation Center Israel Ltd., Citrine Globals Advisory Board and appointed as President of Green Vision Center Israel.

Key Points: 
  • Tel Aviv, May 31, 2022 (GLOBE NEWSWIRE) -- Citrine Global Corp. (OTCQB: CTGL) is pleased to announce Prof. Itamar Grotto joining the Board of Directors of the Companys Israeli subsidiary, Cannovation Center Israel Ltd., Citrine Globals Advisory Board and appointed as President of Green Vision Center Israel.
  • Green Vision Center Israel is part of the Companys strategy to create end-to-end plant-based solutions covering all the infrastructure, facilities, and activities required for developing, manufacturing, and bringing to market innovative plant-based wellness and pharma products.
  • Prof. Grotto said, "I am excited to be part of the Companys team and be the President of Green Vision Center Israel, a first-of-its-kind production and innovation center for pharma and wellness solutions.
  • Citrine Global is a public company traded on the OTCQB and has filed an application with Nasdaq to list the Companys common stock.

DGAP-News: AppYea expands its SleepX patent commercialization portfolio with a non-diluting agreement.

Retrieved on: 
Monday, May 16, 2022
Smartphone, Ben-Gurion University of the Negev, Hypopnea, U.S. Securities and Exchange Commission, Sleep apnea, Snoring, OTC, Solution, Registration statement, Clinical trial, USD, Apnea, Research, FDA, Register, Norwegian Helsinki Committee, Helsinki Committee for Human Rights, Technology, Sale, CAGR, Acquisition, Artificial intelligence, Security (finance), CEO, Sleep, Pharmaceutical industry

AppYea expands its SleepX patent commercialization portfolio with a non-diluting agreement.

Key Points: 
  • AppYea expands its SleepX patent commercialization portfolio with a non-diluting agreement.
  • AppYea (OTC: APYP) announced that its subsidiary SleepX, which focuses on the development of accurate wearable monitoring solutions to treat sleep apnea and snoring has signed new commercialization agreement for two additional patents by Ben-Gurion University.
  • This is compared to traditional technologies that use physical sensors to detect apnea in overnight sleep labs.
  • Neither APYP nor SLEEPX are subject to the reporting requirements of the Securities and Exchange Commission.